Nature, Published online: 11 November 2026; doi:10.1038/d41586-026-03640-9
A promising biotechnology company developed a new approach that might treat a rare disease — but its sole employee didn’t do all the work.AI & ML
Anthropic bought a one-person, AI-powered biotech: is this drug discovery’s future?
Nature News0 views
Source：https://www.nature.com/articles/d41586-026-03640-9
PreviousRattlesnakes have personalities too — to venomous effectNextEngineered bacteria are weaning farms away from synthetic fertilizers
Related posts
Attackers Say 'Hello' to a Different Scale of Cloud Attack
0Dark Reading
Memory price skyrockets as demand for AI data centers drives 369% year-over-year surge
0TechRadar
Apple reportedly met with Thai officials over spyware alerts sent to politicians
09to5Mac
I Saw the Future of Robotics in a Virtual Duck That Chases My Cat
0Wired
Taiwan’s chipmaking giant TSMC to invest $1B in Anthropic, OpenAI
0Ars Technica
CoreWeave turns to customer prepayments, shorter contracts to fund AI growth
0TechCrunch